Document Detail


Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial.
MedLine Citation:
PMID:  11452676     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapy with individual 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been shown conclusively to diminish coronary event rates and mortality in both primary and secondary prevention. To date, scant attention has been paid to whether initiation of such regimens in the hospital phase of acute coronary syndromes might confer cardioprotective benefits. The purpose of this study was to determine the safety and tolerability of early initiation of statin therapy in patients with acute coronary syndromes. In this randomised, double-blind, three-month, pilot study, 100 patients with acute myocardial infarction or unstable angina and low-density lipoprotein cholesterol > 3.5 mmol/l were randomly assigned to pravastatin 40 mg daily or placebo initiated within 48 hours of hospital admission. Pravastatin proved safe and well tolerated in these patients, who were well matched at baseline. No statistically significant differences in death, MI and drug-related adverse events were observed in the pravastatin group compared with control subjects. This pilot study shows that therapy with pravastatin early after an acute coronary event is safe and well tolerated. Larger, long-term studies are needed to confirm these findings.
Authors:
F R Den Hartog; P M Van Kalmthout; T T Van Loenhout; H J Schaafsma; H Rila; F W Verheugt
Related Documents :
9551596 - Lipid-lowering therapy after coronary revascularization: the interventional cardiologis...
10376196 - Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils.
8829016 - Clinical pharmacologic concepts for the rational selection and use of drugs for the man...
12841346 - Effect of coenzyme q10 on risk of atherosclerosis in patients with recent myocardial in...
2598426 - Prognosis in patients with low left ventricular ejection fraction after myocardial infa...
9412776 - Effects of lipid lowering therapy on progression of coronary and carotid artery disease.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International journal of clinical practice     Volume:  55     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-16     Completed Date:  2001-08-16     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  300-4     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Gelderse Vallei Hospital, Ede, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Angina, Unstable / drug therapy*,  prevention & control
Anticholesteremic Agents / administration & dosage*,  adverse effects
Double-Blind Method
Female
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*,  prevention & control
Pilot Projects
Pravastatin / administration & dosage*,  adverse effects
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 81093-37-0/Pravastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The health economic impact of antidepressant usage from a payer's perspective: a multinational study...
Next Document:  Safety, effectiveness and cost efficacy of diagnostic electrophysiology and radiofrequency ablation ...